ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
CHRM2 and GRIN2A polymorphisms in tardive dyskinesia and cognitive impairments in Chinese Han schizophrenia.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The genetic mechanisms underlying tardive dyskinesia (TD) are crucial for understanding its development. This study aimed to examine the association between single nucleotide polymorphisms (SNPs) in the Glutamate Ionotropic Receptor NMDA Type Subunit (GRIN2A) and Cholinergic Receptor Muscarinic 2 (CHRM2) genes and their interactions with the susceptibility, severity of symptoms, and cognitive function of TD in Chinese Han patients with schizophrenia (SZ). A total of 216 SZ patients were categorized into TD and those without TD (WTD) groups. DNA was extracted using the high-salt method, and the SNP genotyping was conducted. TD severity was assessed using the Abnormal Involuntary Movement Scale (AIMS), while cognitive function was measured with the Repetitive Battery for the Assessment of Neuropsychological Status (RBANS). The GRIN2A rs7206256 GG + GA genotypes showed significantly different frequencies compared to the AA genotype (OR = 0.32, 95% CI = 0.13-0.79, p = 0.007). TD patients with the rs7206256 GG genotype exhibited higher limb trunk scores (p < 0.01), and lower orofacial scores (p < 0.01). Additionally, significant differences in attention and total RBANS scores were observed across CHRM2 rs2061174 genotypes within the TD group (F = 2.55, p = 0.05; F = 5.08, p = 0.05). The combination of CHRM2 (rs1824024)-GRIN2A (rs7206256) and CHRM2 (rs2061174)-GRIN2A (rs7206256) were identified as the best two-SNP model for predicting TD risk (p = 0.05). In Chinese Han SZ patients, GRIN2A rs7206256 is associated with increased susceptibility to TD and greater symptom severity. CHRM2 rs2061174 might influence cognitive dysfunction in TD, and a potential gene-gene interaction between GRIN2A and CHRM2 loci was observed. These findings need confirmation through larger, multi-center studies with diverse populations and functional genomic analyses to uncover the biological mechanisms involved.
Indexed as
Identifiers
40445323What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.